...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>AIDS Research and Human Retroviruses >Dual Raltegravir-Etravirine Combination as Maintenance Regimen in Virologically Suppressed HIV-1-Infected Patients
【24h】

Dual Raltegravir-Etravirine Combination as Maintenance Regimen in Virologically Suppressed HIV-1-Infected Patients

机译：双raltegravir-etravirine组合作为病毒学抑制的艾滋病毒治疗中的维护方案

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Nucleoside reverse transcriptase inhibitor (NRTI)- and protease inhibitor (PI)-sparing antiretroviral regimens may be useful in selected human immune deficiency virus (HIV)-infected patients with resistance or intolerance to these drug classes. This was an observational prospective study of patients on suppressive antiretroviral therapy containing two NRTIs plus one ritonavir-boosted PI who switched to a dual regimen containing raltegravir plus etravirine. Patients were required not to have prior virological failure to raltegravir and to have efficacy of etravirine shown through the genotypic resistance assay in case of prior non-nucleoside reverse transcriptase inhibitor (NNRTI) virological failure. As a whole, 38 patients were enrolled. The mean duration of current regimen was 4.3 years, and the reason for simplification was toxicity in 29 patients and resistance to NRTIs in 9 patients. After switching, the percentage of patients with HIV RNA <20 copies/ml at week 48 was 81.6% in the intent-to-treat-exposed analysis. The switch led to a significant reduction in the mean serum triglyceride levels (?81.2?mg/dl), in the mean total cholesterol levels (?44.3?mg/dl), and in the prevalence of tubular proteinuria (?30.2%), with a significant increase in the mean phosphoremia (+0.52?mg/dl) and in both mean lumbar and femoral neck bone mineral density (+6.5% and +4.7%, respectively). Two patients (5.2%) had virological failure due to suboptimal adherence, and five subjects (13.1%) discontinued treatment due to adverse events. In our study, simplification to the dual-therapy raltegravir plus etravirine was associated with a good efficacy and tolerability, in addition to a favorable effect on kidney, bone, and serum lipids.
机译：核苷逆转录酶抑制剂（NRTI） - 和蛋白酶抑制剂（PI） - 卡型抗逆转录病毒方案可用于选定的人免疫缺陷病毒（HIV） - 抗性抗性或不耐受这些药物类别的患者。这是抑制抗逆转录病毒治疗患者的观察前瞻性研究，含有两种NRTIS加上一个Ritonavir-Boosted Pi，他们切换到含有Raltegravir加etravirine的双方案。在先前的非核苷逆转录酶抑制剂（NNRTI）病毒学失败的情况下，不需要对RALTEGRAVIR具有先前病毒学失败并且具有通过基因型抗性测定所示的替代毒素的疗效。整体而言，已注册38名患者。当前方案的平均持续时间为4.3岁，简化的原因是29名患者的毒性和9例患者对NRTIS的抵抗力。切换后，在第48周的HIV RNA <20拷贝/ ml患者的百分比在意图暴露的分析中为81.6％。该开关导致平均血清甘油三酯水平（αmg/ dl）的显着降低，平均总胆固醇水平（αmg/ dl）和管状蛋白尿的患病率（？30.2％），平均磷脂（+0.52μmg/ dl）和平均腰部和股骨颈骨密度（分别分别为股骨颈骨矿物密度（分别分别为股骨颈骨密度（分别为+ 4.7％）。由于次优依从性，两名患者（5.2％）具有病毒学故障，并且由于不良事件而导致的五个受试者（13.1％）停止治疗。在我们的研究中，除了对肾脏，骨和血清脂质的有利影响外，对双治疗RALTEGRAVIR加etravirine的简化与良好的疗效和耐受性有关。

著录项

  • 来源
  • 作者

    Leonardo Calza; Eleonora Magistrelli; Vincenzo Colangeli; Roberto Manfredi; Marco Borderi; Nicolo Rossi; Matteo Conti; Rita Mancini; Pierluigi Viale;

  • 作者单位

    Department of Medical and Surgical Sciences Clinics of Infectious Diseases “Alma Mater Studiorum;

    Department of Medical and Surgical Sciences Clinics of Infectious Diseases “Alma Mater Studiorum;

    Department of Medical and Surgical Sciences Clinics of Infectious Diseases “Alma Mater Studiorum;

    Department of Medical and Surgical Sciences Clinics of Infectious Diseases “Alma Mater Studiorum;

    Department of Medical and Surgical Sciences Clinics of Infectious Diseases “Alma Mater Studiorum;

    Department of Medical and Surgical Sciences Clinics of Infectious Diseases “Alma Mater Studiorum;

    Centralized Laboratory “Alma Mater Studiorum” University of Bologna S. Orsola-Malpighi Hospital;

    Centralized Laboratory “Alma Mater Studiorum” University of Bologna S. Orsola-Malpighi Hospital;

    Department of Medical and Surgical Sciences Clinics of Infectious Diseases “Alma Mater Studiorum;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 传染病;
  • 关键词

    raltegravir; etravirine; dual therapy; switch; toxicity;

    机译：Raltegravir;etravirine;双重治疗;开关;毒性;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号